Breckenridge Pharmaceutical, Inc recalls Duloxetine Delayed-Release Capsules USP
FDA Class II
FDA classified this recall as Class II: the product may cause health problems that are temporary or can be treated; the chance of serious harm is remote.
- Hazard
- CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.
- Products
-
- Duloxetine Delayed-Release Capsules USP
- Where it was sold
-
US Nationwide.
Nationwide
- Units affected
- 343,344 bottles
- About this recall
- Duloxetine Delayed-Release Capsules USP, 30 mg, a.) 90-count bottles (NDC# 51991-747-90), b.) 1000-count bottles (NDC 51991-747-10), Rx Only, Manufactured by Towa Pharmaceutical Europe, S.L. Distributed by Breckenridge Pharmaceutical, Inc. Berkeley Heights, NJ 07922